"Drug Repositioning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The deliberate and methodical practice of finding new applications for existing drugs.
| Descriptor ID |
D058492
|
| MeSH Number(s) |
E05.295.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Repositioning".
Below are MeSH descriptors whose meaning is more specific than "Drug Repositioning".
This graph shows the total number of publications written about "Drug Repositioning" by people in this website by year, and whether "Drug Repositioning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 3 | 3 | 6 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Repositioning" by people in Profiles.
-
Freidel MR, Armen RS. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike. Viruses. 2024 04 30; 16(5).
-
Ponzini FM, Schultz CW, Leiby BE, Cannaday S, Yeo T, Posey J, Bowne WB, Yeo C, Brody JR, Lavu H, Nevler A. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma. BMJ Open. 2023 10 17; 13(10):e073839.
-
Kutkat O, Moatasim Y, Al-Karmalawy AA, Abulkhair HS, Gomaa MR, El-Taweel AN, Abo Shama NM, GabAllah M, Mahmoud DB, Kayali G, Ali MA, Kandeil A, Mostafa A. Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies. Sci Rep. 2022 07 28; 12(1):12920.
-
Onoufriadis A, Proudfoot LE, Ainali C, Torre D, Papanikolaou M, Rayinda T, Rashidghamat E, Danarti R, Mellerio JE, Ma'ayan A, McGrath JA. Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing. Exp Dermatol. 2022 03; 31(3):420-426.
-
Karatzas E, Kakouri AC, Kolios G, Delis A, Spyrou GM. Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action. PLoS One. 2021; 16(4):e0249687.
-
Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep. 2021 04 06; 35(1):108959.
-
Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021 May 05; 898:173988.
-
Chen A, Patel S, Alcusky M, Maio V. Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts? Am J Med Qual. 2021 Mar-Apr 01; 36(2):122-124.
-
Sharma P, McAlinden KD, Ghavami S, Deshpande DA. Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check? Eur J Pharmacol. 2021 Apr 15; 897:173928.
-
Gomella LG. COVID-19 and The Prostate Cancer Connection. Can J Urol. 2020 10; 27(5):10346.